U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07123103) titled 'A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors' on Aug. 08.
Brief Summary: The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Study Start Date: Aug. 11
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: XB371
Intravenous (IV) infusion.
Recruitment Status: RECRUITING
Sponsor: Exelixis
Published by HT Digital Content Services with permission from Health Daily Digest....